OSE Immunotherapeutics Recebe € 8,4 M em Financiamento Público para Apoiar o Ensaio Clínico de Fase 3 de Registro da Vacina contra o Câncer Tedopi® no Câncer de Pulmão
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
